FDA OKs Merck tablet to reduce ragweed allergies

by The Associated Press

U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.

Ragwitek tablets dissolve quickly under the tongue. Patients are to take one daily, from three months before ragweed season begins until it ends, for a few years. The Food and Drug Administration approved it for patients aged 18 through 65.

Whitehouse Station, N.J.-based Merck's tablet for spring grass allergies, Grastek, was approved Monday for patients aged 5 to 65.

Both offer an alternative to medicines that just temporarily relieve symptoms or years of uncomfortable allergy shots.

The shots and tablets work by gradually tamping down immune response to allergy-triggering substances and reducing sneezing, runny noses and itchy, watery eyes.

Ragwitek and Grastek should be available in pharmacies by April 30.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Merck says FDA reviewing its ragweed allergy therapy

May 08, 2013

Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

Merck: FDA reviewing tablet to eliminate allergy

Mar 27, 2013

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that gradually reduces allergy symptoms over time, rather than just temporarily relieving ...

Recommended for you

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.